Neurocrine Biosciences has commenced a Phase IIb trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854, for the treatment of tardive dyskinesia.

The twelve-week Kinect study is a randomised, parallel, double-blind, placebo-controlled trial of 120 subjects with moderate-to-severe tardive dyskinesia and underlying schizophrenia or schizoaffective disorder.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The study is designed to assess two doses of once-daily NBI-98854 over a six-week placebo-controlled dosing period.

Neurocrine Biosciences chief medical officer Christopher O’Brien said the clinical trial is NBI-98854’s next development step.

"The Kinect Study incorporates key refinements to improve the appropriateness of tardive dyskinesia subjects, reduce the variability in AIMS assessments, and expand our dose response database," O’Brien said.

See Also:

"This study will provide us with the data necessary to develop the Phase III programme for NBI-98854."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company expects the topline data from the trial in the second quarter of 2013.

According to the study design, the two NBI-98854 dosing groups will consist of a 50mg group for six weeks, and a group that will begin at 100mg for the initial two weeks, then convert to a 50mg for the final four weeks of placebo-controlled dosing.

After the placebo-controlled dosing, all subjects will enter a six-week open label safety extension of 50mg of NBI-98854, administered once-daily with additional Abnormal Involuntary Movement Scale (AIMS) assessments.

A comparison of placebo vs active scores utilising AIMS at the end of week six, is the primary endpoint of the study.

The independent panel will determine if the subject meets the AIMS severity criteria to be eligible for the Kinect Study.